Navigation Links
Renessa® Treatment for Stress Incontinence: Three Year Clinical Results Presented

NEWARK, Calif., Oct. 13, 2011 /PRNewswire/ -- Novasys Medical, Inc., a developer of innovative therapies in women's health, announced today that a poster describing results from a prospective three year clinical trial of its non-surgical Renessa® treatment for stress urinary incontinence (SUI) in women was presented at two professional society meetings in September 2011: the annual national Scientific Meeting of the American Urogynecologic Society (AUGS) and the South Central Section of the American Urological Association.

The poster, authored by Harvey A. Winkler, MD, co-chief of Urogynecology at North Shore-LIJ University in Manhasset, New York, showed that an estimated 71% of patients experienced an improvement in quality of life at 36 months post-treatment. "These results confirm that the majority of patients treated with the non-surgical Renessa procedure experience lasting improvements in symptoms and quality of life," said Dr. Winkler. "The procedure also appears to be very safe, as no serious adverse events were reported at any time during the follow-up period," he added.

Surgical procedures for SUI often involve permanent implantation of a strip of synthetic mesh to provide additional support to the urethra. In July 2011 the U.S. Food and Drug Administration (FDA) issued its second Safety Communication regarding serious complications reported with mesh placed transvaginally in pelvic organ prolapse (POP) surgical procedures and is continuing to monitor adverse events associated with mesh used to repair both POP and SUI. The most common serious complications reported for mesh procedures for SUI include pelvic pain, mesh erosion through vaginal tissue, and groin injury and pain [source: FDA Perspective on Surgical Mesh for Stress Urinary Incontinences (SUI), presentation at FDA Obstetrics-Gynecology Devices Panel of the Medical Device Advisory Committee, September 9, 2011,].

"Many studies have shown that SUI has a significant negative impact on the lives of millions of women," said Scott Cramer, Novasys Medical President and Chief Executive Officer. "Given concerns about the risks of mesh used in prolapse and incontinence surgery, it is more important than ever for women and their physicians to have safe, effective, less invasive treatment options. When conservative therapies for SUI such as Kegel exercises fail, Renessa is the logical next step in the treatment pathway before proceeding to a more invasive surgical procedure."

Female Stress Urinary Incontinence (SUI)

SUI is the involuntary leakage of urine associated with coughing, sneezing, laughing and recreational activities. Caused by a variety of factors -- most commonly childbirth -- SUI often restricts the social, professional, and personal lives of an estimated 15 million women in the U.S. With currently available SUI therapies, many patients and physicians have concerns about safety, recovery, compliance and/or effectiveness. Experts estimate 80-90% of women with SUI do not pursue treatment of any kind.

About Renessa

The FDA-cleared Renessa System is an innovative, non-surgical approach to treating SUI in women. The Renessa procedure can be performed in the convenience of a physician's office using local anesthesia. There are no incisions, and no implants or foreign materials are left in the body after the treatment is complete. Recovery is rapid and comfortable, with most patients able to return to normal daily activities the same or the next day.

About Novasys Medical

Novasys Medical, Inc. is a privately held, venture-backed company which develops innovative therapies in women's health. The company's first product, the Renessa System, is a proprietary, non-surgical approach to the treatment of stress urinary incontinence (SUI) in women.

Women suffering from stress urinary incontinence can learn more about the Renessa treatment by visiting Physicians interested in more details about the procedure can visit

For more information, please visit or call (510) 226-4060.

SOURCE Novasys Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
3. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
4. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
5. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
8. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. Many Heart Attack Patients Dont Get Best Emergency Treatment
11. New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results
Post Your Comments:
(Date:10/11/2017)... Texas , Oct. 11, 2017  True ... services, has amplified its effort during National Breast ... about hereditary cancer risks. ... of Clinical Oncology calculated that more than 10 ... have inherited mutations in BRCA1 or BRCA2 and have ...
(Date:10/5/2017)... 5, 2017  In response to the nationwide ... Maxillofacial Surgeons (AAOMS) released prescribing recommendations that urge ... used as a first-line therapy to manage a ... Recognizing the value and importance ... "Opioid Prescribing: Acute and Postoperative Pain Management" stresses ...
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Apple Rehab Shelton Lakes , which ... evacuation of the facility as part of a disaster drill on October 3rd. , ... and Shelton City Emergency Manager, as well as the Connecticut Long Term Care ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... the most popular and least understood books in the Holy Scriptures, Revelation. The Book ... have baffled scholars for centuries. Many have tossed it off as mere rubbish, but ...
(Date:10/12/2017)... ... 12, 2017 , ... First Healthcare Compliance (FHC), an industry ... a range of technology and learning solutions at the 68th Annual American Healthcare ... be held October 14–18, 2017 at the Mandalay Bay Resort in Las Vegas, ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical ... Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. ... honor of Morris F. Collen, a pioneer in the field of medical informatics, this ...
(Date:10/12/2017)... D.C. (PRWEB) , ... October 12, 2017 , ... Leading ... their peers in Washington, D.C., for the 49th Congress of the International Society ... ., Vice President of the Center for Cancer and Blood Disorders at ...
Breaking Medicine News(10 mins):